All In Biotech

Drug Trial Radar · NCT00784862

ATAC - Pharmacokinetics (PK) Sub-Protocol

A Randomised, Double Blind Trial to Assess the Pharmacokinetics of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: May 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 9,358 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

9,358

Actual

Start

Jun 1998

Primary completion

Not stated

Study completion Mar 1999

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the effect of ARIMIDEX on the pharmacokinetics of tamoxifen and the effects of tamoxifen on the pharmacokinetics of ARIMIDEX..

Conditions

  • Breast Cancer

Interventions

  • AnastrozoleDrug

    1mg, orally, once daily

  • TamoxifenDrug

    20mg, orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Steady state plasma trough concentrations of tamoxifen, desmethyltamoxifen and anastrozoleTime frame: 24±4 hours after previous dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.